Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study

PRÉCIS: This study demonstrates the efficacy and safety of once-daily 0.002% omidenepag isopropyl (OMDI) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) who do not respond or respond poorly to latanoprost. PURPOSE: The purpose of this study was to evaluate the intrao...

Descripción completa

Detalles Bibliográficos
Autores principales: Panarelli, Joseph F., Bowden, Eileen C., Tepedino, Michael E., Odani-Kawabata, Noriko, Pei, Zifan, McLaurin, Eugene B., Ropo, Auli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
New Glaucoma Insights: Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681282/
https://www.ncbi.nlm.nih.gov/pubmed/37853676
http://dx.doi.org/10.1097/IJG.0000000000002321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681282/
https://www.ncbi.nlm.nih.gov/pubmed/37853676
http://dx.doi.org/10.1097/IJG.0000000000002321

Ejemplares similares